NYLIM
RCUS icon

New York Life Investment Management’s Arcus Biosciences RCUS Stock Holding History

New York Life Investment Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-21,416
Closed -$404K – 1214
2024
Q1 		$404K Buy
21,416
+2,336
+12% +$40.4K ﹤0.01% 808
2023
Q4 		$364K Sell
19,080
-440
-2% -$7.03K ﹤0.01% 1081
2023
Q3 		$350K Sell
19,520
-3,075
-14% -$61.8K ﹤0.01% 1010
2023
Q2 		$459K Sell
22,595
-3,578
-14% -$68.1K ﹤0.01% 788
2023
Q1 		$477K Buy
+26,173
New +$500K 0.01% 957

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

New York Life Investment Management's RCUS Position: Q2 2024 in Review

New York Life Investment Management sold out of Arcus Biosciences (RCUS) in Q2 2024, closing a stake of 21,416 shares — an estimated $404K sold.

New York Life Investment Management first reported a position in RCUS in Q1 2023 and held it in 5 quarters. The position peaked at $477K in Q1 2023. 193 funds tracked by Wall St. Rank hold RCUS as of Q2 2024.

  • New York Life Investment Management reported no remaining Arcus Biosciences position as of Q2 2024 after selling out during the quarter.
  • New York Life Investment Management sold 21,416 Arcus Biosciences shares in Q2 2024, an estimated $404K.
  • New York Life Investment Management first reported a position in Arcus Biosciences in Q1 2023 and held it in 5 quarters.
  • New York Life Investment Management's Arcus Biosciences position peaked at $477K in Q1 2023.
  • 193 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.